APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs Based on Gene Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs Based on Gene Therapy Market Analysis and Forecast 2026-2032

30 December 2025194 pages

Choose your research edition.

Industry ResearchDrugs Based on Gene Therapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs Based on Gene Therapy Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Drugs Based on Gene Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs Based on Gene Therapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs Based on Gene Therapy Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Drugs Based on Gene Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs Based on Gene Therapy include Akcea Therapeutics, Alnylam Pharmaceuticals, AnGes, Biogen, Bluebird bio, Gilead Sciences, Human Stem Cells Institute, Orchard Therapeutics and Sarepta Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs Based on Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs Based on Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs Based on Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs Based on Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs Based on Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs Based on Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.

Drugs Based on Gene Therapy Segment by Company

Akcea Therapeutics

Alnylam Pharmaceuticals

AnGes

Biogen

Bluebird bio

Gilead Sciences

Human Stem Cells Institute

Orchard Therapeutics

Sarepta Therapeutics

SIBIONO

Spark Therapeutics

Sunway Biotech

Amgen

Novartis

Drugs Based on Gene Therapy Segment by Type

Viral Gene Therapy

Non-viral Gene Therapy

Drugs Based on Gene Therapy Segment by Application

Neurological Diseases

Cancer

Other

Drugs Based on Gene Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on Gene Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs Based on Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs Based on Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs Based on Gene Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs Based on Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Viral Gene Therapy Major Player Table 3. Non-viral Gene Therapy Major Player Table 4. Global Drugs Based on Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Neurological Diseases Major Player Table 6. Cancer Major Player Table 7. Other Major Player Table 8. Drugs Based on Gene Therapy Industry Trends Table 9. Drugs Based on Gene Therapy Industry Drivers Table 10. Drugs Based on Gene Therapy Industry Opportunities and Challenges Table 11. Drugs Based on Gene Therapy Industry Restraints Table 12. Global Drugs Based on Gene Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Drugs Based on Gene Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Drugs Based on Gene Therapy Market Share by Region (2021-2026) Table 15. Global Drugs Based on Gene Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Drugs Based on Gene Therapy Market Share by Region (2027-2032) Table 17. Global Drugs Based on Gene Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Drugs Based on Gene Therapy Revenue Market Share by Players (2021-2026) Table 19. Global Drugs Based on Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Drugs Based on Gene Therapy Key Players Headquarters & Area Served Table 21. Global Drugs Based on Gene Therapy Players, Product Type & Application Table 22. Global Drugs Based on Gene Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Drugs Based on Gene Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Drugs Based on Gene Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Drugs Based on Gene Therapy Revenue Market Share by Type (2021-2026) Table 29. Global Drugs Based on Gene Therapy Revenue Market Share by Type (2027-2032) Table 30. Global Drugs Based on Gene Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Drugs Based on Gene Therapy Revenue Market Share by Application (2021-2026) Table 34. Global Drugs Based on Gene Therapy Revenue Market Share by Application (2027-2032) Table 35. Akcea Therapeutics Company Information Table 36. Akcea Therapeutics Business Overview Table 37. Akcea Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Akcea Therapeutics Drugs Based on Gene Therapy Product Portfolio Table 39. Akcea Therapeutics Recent Development Table 40. Alnylam Pharmaceuticals Company Information Table 41. Alnylam Pharmaceuticals Business Overview Table 42. Alnylam Pharmaceuticals Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Alnylam Pharmaceuticals Drugs Based on Gene Therapy Product Portfolio Table 44. Alnylam Pharmaceuticals Recent Development Table 45. AnGes Company Information Table 46. AnGes Business Overview Table 47. AnGes Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. AnGes Drugs Based on Gene Therapy Product Portfolio Table 49. AnGes Recent Development Table 50. Biogen Company Information Table 51. Biogen Business Overview Table 52. Biogen Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Biogen Drugs Based on Gene Therapy Product Portfolio Table 54. Biogen Recent Development Table 55. Bluebird bio Company Information Table 56. Bluebird bio Business Overview Table 57. Bluebird bio Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Bluebird bio Drugs Based on Gene Therapy Product Portfolio Table 59. Bluebird bio Recent Development Table 60. Gilead Sciences Company Information Table 61. Gilead Sciences Business Overview Table 62. Gilead Sciences Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Gilead Sciences Drugs Based on Gene Therapy Product Portfolio Table 64. Gilead Sciences Recent Development Table 65. Human Stem Cells Institute Company Information Table 66. Human Stem Cells Institute Business Overview Table 67. Human Stem Cells Institute Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Human Stem Cells Institute Drugs Based on Gene Therapy Product Portfolio Table 69. Human Stem Cells Institute Recent Development Table 70. Orchard Therapeutics Company Information Table 71. Orchard Therapeutics Business Overview Table 72. Orchard Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Orchard Therapeutics Drugs Based on Gene Therapy Product Portfolio Table 74. Orchard Therapeutics Recent Development Table 75. Sarepta Therapeutics Company Information Table 76. Sarepta Therapeutics Business Overview Table 77. Sarepta Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Sarepta Therapeutics Drugs Based on Gene Therapy Product Portfolio Table 79. Sarepta Therapeutics Recent Development Table 80. SIBIONO Company Information Table 81. SIBIONO Business Overview Table 82. SIBIONO Drugs Based on Gene Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. SIBIONO Drugs Based on Gene Therapy Product Portfolio Table 84. SIBIONO Recent Development Table 85. Spark Therapeutics Company Information Table 86. Spark Therapeutics Business Overview Table 87. Spark Therapeutics Drugs Based on Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Spark Therapeutics Drugs Based on Gene Therapy Product Portfolio Table 89. Spark Therapeutics Recent Development Table 90. Sunway Biotech Company Information Table 91. Sunway Biotech Business Overview Table 92. Sunway Biotech Drugs Based on Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sunway Biotech Drugs Based on Gene Therapy Product Portfolio Table 94. Sunway Biotech Recent Development Table 95. Amgen Company Information Table 96. Amgen Business Overview Table 97. Amgen Drugs Based on Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Amgen Drugs Based on Gene Therapy Product Portfolio Table 99. Amgen Recent Development Table 100. Novartis Company Information Table 101. Novartis Business Overview Table 102. Novartis Drugs Based on Gene Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Novartis Drugs Based on Gene Therapy Product Portfolio Table 104. Novartis Recent Development Table 105. North America Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 106. North America Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 107. North America Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 108. North America Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 109. North America Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. North America Drugs Based on Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Drugs Based on Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 112. Europe Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 113. Europe Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 114. Europe Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 115. Europe Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 116. Europe Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Europe Drugs Based on Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 118. Europe Drugs Based on Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 119. China Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 120. China Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 121. China Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 122. China Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 123. Asia Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 124. Asia Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 125. Asia Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 126. Asia Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 127. Asia Drugs Based on Gene Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Asia Drugs Based on Gene Therapy Revenue by Region (US$ Million) & (2021-2026) Table 129. Asia Drugs Based on Gene Therapy Revenue by Region (US$ Million) & (2027-2032) Table 130. SAMEA Drugs Based on Gene Therapy Revenue by Type (2021-2026) & (US$ Million) Table 131. SAMEA Drugs Based on Gene Therapy Revenue by Type (2027-2032) & (US$ Million) Table 132. SAMEA Drugs Based on Gene Therapy Revenue by Application (2021-2026) & (US$ Million) Table 133. SAMEA Drugs Based on Gene Therapy Revenue by Application (2027-2032) & (US$ Million) Table 134. SAMEA Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 135. SAMEA Drugs Based on Gene Therapy Revenue by Country (2021-2026) & (US$ Million) Table 136. SAMEA Drugs Based on Gene Therapy Revenue by Country (US$ Million) & (2027-2032) Table 137. Research Programs/Design for This Report Table 138. Authors List of This Report Table 139. Secondary Sources Table 140. Primary Sources List of Figures Figure 1. Drugs Based on Gene Therapy Image Figure 2. Global Drugs Based on Gene Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs Based on Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. Viral Gene Therapy Image Figure 5. Non-viral Gene Therapy Image Figure 6. Global Drugs Based on Gene Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drugs Based on Gene Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Neurological Diseases Image Figure 9. Cancer Image Figure 10. Other Image Figure 11. Global Drugs Based on Gene Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global Drugs Based on Gene Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Drugs Based on Gene Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Drugs Based on Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Drugs Based on Gene Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Drugs Based on Gene Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Drugs Based on Gene Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global Drugs Based on Gene Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drugs Based on Gene Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Drugs Based on Gene Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America Drugs Based on Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Drugs Based on Gene Therapy Revenue Share by Type (2021-2032) Figure 24. North America Drugs Based on Gene Therapy Revenue Share by Application (2021-2032) Figure 25. North America Drugs Based on Gene Therapy Revenue Share by Country (2021-2032) Figure 26. United States Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Drugs Based on Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Drugs Based on Gene Therapy Revenue Share by Type (2021-2032) Figure 31. Europe Drugs Based on Gene Therapy Revenue Share by Application (2021-2032) Figure 32. Europe Drugs Based on Gene Therapy Revenue Share by Country (2021-2032) Figure 33. Germany Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Drugs Based on Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Drugs Based on Gene Therapy Revenue Share by Type (2021-2032) Figure 43. China Drugs Based on Gene Therapy Revenue Share by Application (2021-2032) Figure 44. Asia Drugs Based on Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Drugs Based on Gene Therapy Revenue Share by Type (2021-2032) Figure 46. Asia Drugs Based on Gene Therapy Revenue Share by Application (2021-2032) Figure 47. Asia Drugs Based on Gene Therapy Revenue Share by Region (2021-2032) Figure 48. Japan Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Drugs Based on Gene Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Drugs Based on Gene Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA Drugs Based on Gene Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA Drugs Based on Gene Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Drugs Based on Gene Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-viral Gene Therapy
Applications
  • Neurological Diseases
  • Cancer
  • Other
Companies covered
  • Akcea Therapeutics
  • Alnylam Pharmaceuticals
  • AnGes
  • Biogen
  • Bluebird bio
  • Gilead Sciences
  • Human Stem Cells Institute
  • Orchard Therapeutics
  • Sarepta Therapeutics
  • SIBIONO
  • Spark Therapeutics
  • Sunway Biotech
  • Amgen
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs Based on Gene Therapy Market by Type
  3. 1.2.1 Global Drugs Based on Gene Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Viral Gene Therapy
  5. 1.2.3 Non-viral Gene Therapy
  6. 1.3 Drugs Based on Gene Therapy Market by Application
  7. 1.3.1 Global Drugs Based on Gene Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Neurological Diseases
  9. 1.3.3 Cancer
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Drugs Based on Gene Therapy Market Dynamics
  1. 2.1 Drugs Based on Gene Therapy Industry Trends
  2. 2.2 Drugs Based on Gene Therapy Industry Drivers
  3. 2.3 Drugs Based on Gene Therapy Industry Opportunities and Challenges
  4. 2.4 Drugs Based on Gene Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs Based on Gene Therapy Market Perspective (2021-2032)
  2. 3.2 Global Drugs Based on Gene Therapy Growth Trends by Region
  3. 3.2.1 Global Drugs Based on Gene Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs Based on Gene Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs Based on Gene Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs Based on Gene Therapy Revenue by Players
  2. 4.1.1 Global Drugs Based on Gene Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs Based on Gene Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs Based on Gene Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs Based on Gene Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs Based on Gene Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Drugs Based on Gene Therapy Players, Product Type & Application
  8. 4.5 Global Drugs Based on Gene Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs Based on Gene Therapy Market CR5 and HHI
  11. 4.6.3 2025 Drugs Based on Gene Therapy Tier 1, Tier 2, and Tier 3
5 Drugs Based on Gene Therapy Market Size by Type
  1. 5.1 Global Drugs Based on Gene Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Drugs Based on Gene Therapy Revenue Market Share by Type (2021-2032)
6 Drugs Based on Gene Therapy Market Size by Application
  1. 6.1 Global Drugs Based on Gene Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Drugs Based on Gene Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Akcea Therapeutics
  2. 7.1.1 Akcea Therapeutics Company Information
  3. 7.1.2 Akcea Therapeutics Business Overview
  4. 7.1.3 Akcea Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Akcea Therapeutics Drugs Based on Gene Therapy Product Portfolio
  6. 7.1.5 Akcea Therapeutics Recent Developments
  7. 7.2 Alnylam Pharmaceuticals
  8. 7.2.1 Alnylam Pharmaceuticals Company Information
  9. 7.2.2 Alnylam Pharmaceuticals Business Overview
  10. 7.2.3 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Product Portfolio
  12. 7.2.5 Alnylam Pharmaceuticals Recent Developments
  13. 7.3 AnGes
  14. 7.3.1 AnGes Company Information
  15. 7.3.2 AnGes Business Overview
  16. 7.3.3 AnGes Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AnGes Drugs Based on Gene Therapy Product Portfolio
  18. 7.3.5 AnGes Recent Developments
  19. 7.4 Biogen
  20. 7.4.1 Biogen Company Information
  21. 7.4.2 Biogen Business Overview
  22. 7.4.3 Biogen Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Biogen Drugs Based on Gene Therapy Product Portfolio
  24. 7.4.5 Biogen Recent Developments
  25. 7.5 Bluebird bio
  26. 7.5.1 Bluebird bio Company Information
  27. 7.5.2 Bluebird bio Business Overview
  28. 7.5.3 Bluebird bio Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Bluebird bio Drugs Based on Gene Therapy Product Portfolio
  30. 7.5.5 Bluebird bio Recent Developments
  31. 7.6 Gilead Sciences
  32. 7.6.1 Gilead Sciences Company Information
  33. 7.6.2 Gilead Sciences Business Overview
  34. 7.6.3 Gilead Sciences Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gilead Sciences Drugs Based on Gene Therapy Product Portfolio
  36. 7.6.5 Gilead Sciences Recent Developments
  37. 7.7 Human Stem Cells Institute
  38. 7.7.1 Human Stem Cells Institute Company Information
  39. 7.7.2 Human Stem Cells Institute Business Overview
  40. 7.7.3 Human Stem Cells Institute Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Human Stem Cells Institute Drugs Based on Gene Therapy Product Portfolio
  42. 7.7.5 Human Stem Cells Institute Recent Developments
  43. 7.8 Orchard Therapeutics
  44. 7.8.1 Orchard Therapeutics Company Information
  45. 7.8.2 Orchard Therapeutics Business Overview
  46. 7.8.3 Orchard Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Orchard Therapeutics Drugs Based on Gene Therapy Product Portfolio
  48. 7.8.5 Orchard Therapeutics Recent Developments
  49. 7.9 Sarepta Therapeutics
  50. 7.9.1 Sarepta Therapeutics Company Information
  51. 7.9.2 Sarepta Therapeutics Business Overview
  52. 7.9.3 Sarepta Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Sarepta Therapeutics Drugs Based on Gene Therapy Product Portfolio
  54. 7.9.5 Sarepta Therapeutics Recent Developments
  55. 7.10 SIBIONO
  56. 7.10.1 SIBIONO Company Information
  57. 7.10.2 SIBIONO Business Overview
  58. 7.10.3 SIBIONO Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 SIBIONO Drugs Based on Gene Therapy Product Portfolio
  60. 7.10.5 SIBIONO Recent Developments
  61. 7.11 Spark Therapeutics
  62. 7.11.1 Spark Therapeutics Company Information
  63. 7.11.2 Spark Therapeutics Business Overview
  64. 7.11.3 Spark Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Spark Therapeutics Drugs Based on Gene Therapy Product Portfolio
  66. 7.11.5 Spark Therapeutics Recent Developments
  67. 7.12 Sunway Biotech
  68. 7.12.1 Sunway Biotech Company Information
  69. 7.12.2 Sunway Biotech Business Overview
  70. 7.12.3 Sunway Biotech Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sunway Biotech Drugs Based on Gene Therapy Product Portfolio
  72. 7.12.5 Sunway Biotech Recent Developments
  73. 7.13 Amgen
  74. 7.13.1 Amgen Company Information
  75. 7.13.2 Amgen Business Overview
  76. 7.13.3 Amgen Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Amgen Drugs Based on Gene Therapy Product Portfolio
  78. 7.13.5 Amgen Recent Developments
  79. 7.14 Novartis
  80. 7.14.1 Novartis Company Information
  81. 7.14.2 Novartis Business Overview
  82. 7.14.3 Novartis Drugs Based on Gene Therapy Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Novartis Drugs Based on Gene Therapy Product Portfolio
  84. 7.14.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Drugs Based on Gene Therapy Revenue (2021-2032)
  2. 8.2 North America Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs Based on Gene Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs Based on Gene Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Drugs Based on Gene Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs Based on Gene Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs Based on Gene Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Drugs Based on Gene Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs Based on Gene Therapy Revenue by Country
  11. 8.6.1 North America Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs Based on Gene Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs Based on Gene Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Drugs Based on Gene Therapy Revenue (2021-2032)
  2. 9.2 Europe Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs Based on Gene Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs Based on Gene Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs Based on Gene Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs Based on Gene Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs Based on Gene Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs Based on Gene Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs Based on Gene Therapy Revenue by Country
  11. 9.6.1 Europe Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs Based on Gene Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs Based on Gene Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Drugs Based on Gene Therapy Revenue (2021-2032)
  2. 10.2 China Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs Based on Gene Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs Based on Gene Therapy Revenue by Type (2027-2032)
  5. 10.3 China Drugs Based on Gene Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs Based on Gene Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs Based on Gene Therapy Revenue by Application (2027-2032)
  9. 10.5 China Drugs Based on Gene Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs Based on Gene Therapy Revenue (2021-2032)
  2. 11.2 Asia Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs Based on Gene Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs Based on Gene Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs Based on Gene Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs Based on Gene Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs Based on Gene Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs Based on Gene Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs Based on Gene Therapy Revenue by Country
  11. 11.6.1 Asia Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs Based on Gene Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs Based on Gene Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs Based on Gene Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Drugs Based on Gene Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs Based on Gene Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs Based on Gene Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs Based on Gene Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs Based on Gene Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs Based on Gene Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs Based on Gene Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs Based on Gene Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs Based on Gene Therapy Revenue by Country
  11. 12.6.1 SAMEA Drugs Based on Gene Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs Based on Gene Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs Based on Gene Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst